





AIF Polyclonal Antibody

Catalog Number PA5-27698 Product data sheet

Details	
Size	100 μL
Host/Isotope	Rabbit / IgG
Class	Polyclonal
Туре	Antibody
Immunogen	Recombinant fragment corresponding to a region within amino acids 1 and 170 of Human AIF
Conjugate	Unconjugated
Form	Liquid
Concentration	0.72 mg/mL
Purification	Antigen affinity chromatography
Storage buffer	0.1M tris glycine, pH 7, with 10% glycerol
Contains	0.01% thimerosal
Storage Conditions	Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

Species Reactivity	
Species reactivity	Human
Tested Applications	Dilution *
Immunohistochemistry (Paraffin) (IHC (P))	1:100-1:1,000
Western Blot (WB)	1:500-1:10,000
Immunocytochemistry (ICC/IF)	1:100-1:1,000

^{*} Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.

Product specific information

Recommended positive controls: 293T, A431, HeLa, HepG2, A375. Predicted reactivity: Pig (81%), Bovine (85%). Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.

Background/Target Information

Apoptosis Inducing Factor (AIF) causes chromatin condensation and DNA fragmentation. AIF was recently identified, and cloned. Apoptosis is characterized by several morphological nuclear changes including chromatin condensation and nuclear fragmentation. These changes are triggered by the activation of members of caspase family, caspase activated DNase, and several novel proteins. Like the critical molecules, cytochrome c and caspase-9, in apoptosis, AIF localizes in mitochondria. AIF translocates to the nucleus when apoptosis is induced and induces mitochondria to release the apoptogenic proteins cytochrome c and caspase-9. AIF induces chromatin condensation and large scale DNA fragmentation, which are the hallmarks of apoptosis, of the isolated nucleus and the nucleus in live cells by microinjection and apoptosis stimuli. AIF is highly conserved between human and mouse and widely expressed. Mutations in the AIF gene cause combined oxidative phosphorylation deficiency 6, which results in a severe mitochondrial encephalomyopathy. Alternative splicing results in multiple transcript variants of AIF and a related pseudogene has been identified on chromosome 10.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.


For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization

Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in the Production documentation, specifications and/or accompanying package inserts ("Documentation"). No claim of suitability for use in applications regulated by FDA is made. The warranty provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, this warranty is limited to one year from date of shipment when the Product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample

NO OTHER WARRANTIES, EXPRESS OR IMPLED, ARE GRANTED INCLUDING WITHOUT LIMITATION, IMPLED WARRANTIES OF MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, OR NON INFRINGEMENT, BUYER'S EXCLUSINE REALED FOR ROCKETOR POR REFUND FOR PORTOR PORT OF REFUND FOR PORTOR PORTO




Product Images For AIF Polyclonal Antibody




AIF Antibody (PA5-27698) in WB

AIF Polyclonal Antibody detects AIFM1 protein by Western blot analysis. A. 30 µg 293T whole cell lysate/extract. B. 30 µg A431 whole cell lysate/extract. C. 30 µg HeLa whole cell lysate/extract. D. 30 µg HepG2 whole cell lysate /extract. E. 30 µg A375 whole cell lysate/extract.7.5 % SDS-PAGE. AIF Polyclonal Antibody (Product # PA5-27698) dilution: 1:1,000.



AIF Antibody (PA5-27698)

Antibody specificity was demonstrated by shRNA mediated knockdown of the target protein. 293T cells were transfected with AIF shRNA and decrease in signal intensity was observed in western blot application using AIF antibody [N1N2], N-term (Product # PA5-27698). {KD}



AIF Antibody (PA5-27698) in ICC/IF

AIF Polyclonal Antibody detects AIFM1 protein at Mitochondria by immunofluorescent analysis. Sample: HeLa cells were fixed in 2% paraformaldehyde/culture medium at 37°C for 30 min. Green: AIFM1 protein stained by AIF Polyclonal Antibody (Product # PA5-27698) diluted at 1:500. Blue: Hoechst 33343 staining.



AIF Antibody (PA5-27698) in IHC (P)

Immunohistochemical analysis of paraffin-embedded human gastric cancer, using AIF (Product # PA5-27698) antibody at 1:100 dilution. Antigen Retrieval: EDTA based buffer, pH 8.0, 15 min.


For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in the Production documentation, specifications and/or accompanying package inserts ("Documentation"). No claim of suitability for use in applications regulated by FDA is made. The warranty provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, this warranty is limited to one year from date of shipment when the Product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample until a provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, this warranty is limited to one year from date of shipment when the Product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample.

Uniform the product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample.

NO OTHER WARRANTIES, EXPRESS OR IMPLED, ARE GRANTED INCLUDING WITHOUT LIMITATION, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, OR NON INFRINGEMENT, BUYER'S EXCLUSIVE REALED FOR NON-CONFORMING PRODUCTS DURING THE WARRANTY PERIOD IS LIMITED TO REPLAY, REPLACED RETURN FOR REFULD FOR OR REFULD FOR OR REFULD FOR OR REFULD FOR A R





AIF Antibody (PA5-27698) in IHC (P)

Immunohistochemical analysis of paraffin-embedded human lung cancer, using AIF (Product # PA5-27698) antibody at 1:100 dilution. Antigen Retrieval: EDTA based buffer, pH 8.0, 15 min.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization

Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in the Production documentation, specifications and/or accompanying package insents ("Documentation"). No claim of suitability for use in applications regulated by FDA is made. The varranty provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, this warranty is limited to one year from date of shipment when the Product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample unshall be unshall

NO OTHER WARRANTES, EXPRESS OR MINED, ARE GRANTED INCLUDING WITHOUT LIMITATION, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, OR NON INFRINGEMENT. BLYER'S EXCLUSIVE REMEDY FOR NON-CONFORMING PRODUCTS DURING THE WARRANTY PERIOD IS LIMITED TO REPRIA, REPLACED AND FOR PREVIOUR FOR THE NON-CONFORMING PRODUCTS DURING THE WARRANTY PERIOD IS LIMITED TO REPRIA, REPLACED AND FOR PREVIOUR FOR PRODUCTS. AS THE RESULT OF (I) ACCIDITED TO FORCE MADE (SINGLE MEDICAL PRODUCTS AS THE RESULT OF (I) ACCIDITED TO FORCE MADE (SINGLE MEDICAL PRODUCTS AS THE RESULT OF (I) ACCIDITED TO FORCE MADE (SINGLE MEDICAL PRODUCTS AS THE RESULT OF (I) ACCIDITED TO FORCE MADE (SINGLE MEDICAL PRODUCTS AS THE RESULT OF (I) ACCIDITED TO FORCE MADE (SINGLE MEDICAL PRODUCTS AS THE RESULT OF (I) ACCIDITED TO FORCE MADE (SINGLE MEDICAL PRODUCTS AS THE RESULT OF (I) ACCIDITED TO FORCE MADE (SINGLE MEDICAL PRODUCTS AS THE RESULT OF (I) ACCIDITED TO FORCE MADE (SINGLE MEDICAL PRODUCTS AS THE RESULT OF (I) ACCIDITED TO FORCE MADE (SINGLE MEDICAL PRODUCTS AS THE RESULT OF (I) ACCIDITED TO FORCE MADE (SINGLE MEDICAL PRODUCTS AS THE RESULT OF (I) ACCIDITED TO FORCE MADE (SINGLE MEDICAL PRODUCTS AS THE RESULT OF (I) ACCIDITED TO FORCE MADE (SINGLE MEDICAL PRODUCTS AS THE RESULT OF (I) ACCIDITED TO FORCE MADE (SINGLE MEDICAL PRODUCTS AS THE RESULT OF (I) ACCIDITED TO FORCE MADE (SINGLE MEDICAL PRODUCTS AS THE RESULT OF (I) ACCIDITED TO FORCE MADE (SINGLE MEDICAL PRODUCTS AS THE RESULT OF (I) ACCIDITED TO FORCE MADE (SINGLE MEDICAL PRODUCTS AS THE RESULT OF (I) ACCIDITED TO FORCE MADE (SINGLE MEDICAL PRODUCTS AS THE RESULT OF (I) ACCIDITED TO FORCE MADE (SINGLE MEDICAL PRODUCTS AS THE RESULT OF (I) ACCIDITED TO FORCE MADE (SINGLE MEDICAL PRODUCTS AS THE RESULT OF (I) ACCIDITED TO FORCE MEDICAL PRODUCTS AS THE RESULT OF (I) ACCIDITED TO FORCE MADE (SINGLE MEDICAL PRODUCTS AS THE RESULT OF (I) ACCIDITED TO FORCE MEDICAL PRODUCTS AS THE RESULT OF (I) ACCIDITED TO FORCE MEDICAL PRODUCTS AS THE RESULT OF (I) ACCIDITED TO FORCE MEDICAL PR

